Skip to content 
On the afternoon of May 22, the Nanjing Biomedical Policy Lecture and Enterprise Docking Exchange Activity, jointly sponsored by the Nanjing Biomedical Industry Chain Committee of the Communist Party of China, the Party Working Committee of Nanjing Economic and Technological Development Zone, and the Nanjing Biomedical Industry Promotion Office, was held in Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Yin Jun, deputy secretary of the Party Working Committee of Nanjing Economic and Technological Development Zone, and Guo Yuming, director of the high-tech department of the Municipal Science and Technology Bureau, attended. Heads of more than 60 enterprises from Nanjing Economic Development Zone, Jiangbei New Area and Jiangning District participated in the event.
Guo Yuming comprehensively interpreted the latest biomedical policies in Nanjing, focusing on industrial innovation, achievement transformation, market expansion and other dimensions, from the subsidy policy of “real money” for R&D and innovation, to the ecological construction of “nesting and attracting phoenixes” in industrial parks, and then to the “green channel” of international cooperation, and introduced the policy background, guidance and implementation path in detail. He said that Nanjing’s biomedical policy will provide full-cycle support for enterprises, and strive to create a closed loop of services from technology research and development to market application.
Feng Yan, assistant to the president of Nanjing Chia Tai Tianqing, analyzed the impact of the national pharmaceutical policy on the market layout of pharmaceutical enterprises in combination with the practice of enterprises, and shared the innovative thinking and execution of leading enterprises. Yan Libo, general manager of Kaiyuan Pharmaceutical, shared the key links and risk prevention and control strategies in the international certification process with the theme of “Drugs and Devices Going to Sea” and combined with actual cases.
Chen Hai, President of Jinling Pharmaceutical, Yin Liusong, General Manager of Shenghe Biotechnology, Xu Hanmei, Founder of Anji Biotechnology, and other enterprise leaders exchanged and discussed topics such as “how to deal with the development pain points of biomedical enterprises” and “how to strengthen the collaborative innovation of the industrial chain”. The insights of the entrepreneurs aroused strong resonance among everyone, and the atmosphere of on-site discussion was warm.
